| Biological context | Key mechanism/pathway | Main findings | Study type | Publication | URL | Citation ID |
|---|---|---|---|---|---|---|
| Th2 differentiation / allergic airway inflammation | Distal enhancer ~900 kb downstream of GATA3 (hG900/mG900); enhancer activation correlates with GATA3; 4C-seq chromatin looping from mG900 to Gata3 TSS; BATF-associated loop regulation | hG900 activation strongly correlated with GATA3 levels in human peripheral T-cell subsets; mG900 deletion left steady-state lymphocyte and papain responses largely intact but reduced HDM-induced allergic inflammation and Th2 differentiation; mG900 interacts with Gata3 TSS in Th2 cells (pqac-00000021, pqac-00000023, pqac-00000024, pqac-00000034) | Primary | Kumagai et al., *PNAS*, 2024 | https://doi.org/10.1073/pnas.2320727121 | (pqac-00000021, pqac-00000023, pqac-00000024, pqac-00000034) |
| Th2 differentiation / type 2 immunity | Upstream signaling to GATA3 via IL-4/STAT6, plus TCR, IL-2, IL-7, NOTCH; GATA3 contributes to 3D genome architecture and H3K4me1 reconfiguration | Review synthesizes that GATA3 is the master TF driving TH2 genes and repressing alternate TH fates; deletion of GATA3 reduces chromatin loops in TH2 cells; enhancer example includes an ILC2-specific enhancer ~674 kb downstream of Gata3 (pqac-00000031) | Review | Szeto et al., *Current Opinion in Immunology*, 2024 | https://doi.org/10.1016/j.coi.2024.102483 | (pqac-00000031) |
| ILC2 development | ILC2-specific tandem GATA3-related super-enhancers (G3SE) that induce high GATA3 in IL17RB+PD-1− late ILC2-committed precursors | G3SE-deficient mice showed ILC2 deficiency in bone marrow, lung, liver, and small intestine with minimal impact on other ILC lineages or Th2 cells; 624 super-enhancers identified; IL17RB+PD-1− late precursors increased ~6-fold in G3SEKO mice, consistent with a block in transition to ST2+ ILC2s (pqac-00000026, pqac-00000025, pqac-00000027) | Primary | Furuya et al., *Nature Communications*, 2024 | https://doi.org/10.1038/s41467-024-49881-y | (pqac-00000026, pqac-00000025, pqac-00000027) |
| Th2 and ILC2 immunobiology | Integrative signaling framework: IL-2 and IL-4; Wnt and Notch; cytokine-independent stabilization of Th2 function | GATA3 is defined as a dual zinc-finger TF essential for naïve CD4+ T-cell differentiation into Th2 cells and upregulated in CD4 T cells and ILCs; review emphasizes integration of IL-2/IL-4 with Wnt/Notch signaling in type 2 immunity (pqac-00000033) | Review | Bacha et al., *Cells*, 2024 | https://doi.org/10.3390/cells13242127 | (pqac-00000033) |
| Breast luminal epithelium / breast cancer | GATA3–AR nuclear interaction; AR-dependent enrichment of GATA3 chromatin binding; induction of luminal differentiation genes | AR activation by DHT increased nuclear AR–GATA3 interactions; silencing GATA3 reduced but did not abolish AR DNA binding/transactivation; AR/GATA3 co-occupancy upregulated luminal genes including **EHF** and **KDM4B** and was associated with AR-mediated growth inhibition in ER+ and ER− breast cancer models (pqac-00000015) | Primary | Hosseinzadeh et al., *Genome Biology*, 2024 | https://doi.org/10.1186/s13059-023-03161-y | (pqac-00000015) |
| ER-positive breast cancer / real-world prognostic use | Nuclear GATA3 IHC and GATA3 mRNA as biomarkers of luminal state, EMT status, and endocrine benefit | High nuclear GATA3 associated with lower distant recurrence (HR 0.60, 95% CI 0.39–0.93); high/intermediate GATA3 mRNA predicted tamoxifen benefit (HR 0.39, 95% CI 0.24–0.64), whereas low GATA3 did not clearly benefit (HR 0.61, 95% CI 0.31–1.17); after 5 years, no further benefit in low GATA3 group (HR 1.10, 95% CI 0.46–2.61) versus higher GATA3 (HR 0.35, 95% CI 0.19–0.64); interaction p=0.033; 70% of tumors had high nuclear GATA3, and among ER+ tumors high nuclear GATA3 was seen in 84% versus 19% of ER− tumors (pqac-00000011, pqac-00000012, pqac-00000010, pqac-00000013, pqac-00000035) | Primary | Sandström et al., *NPJ Breast Cancer*, 2024 | https://doi.org/10.1038/s41523-024-00688-6 | (pqac-00000011, pqac-00000012, pqac-00000010, pqac-00000013, pqac-00000035) |
| Breast cancer mutation biology / luminal identity | ZnFn2 mutation-driven transcriptional reprogramming; altered DNA binding; pioneer-factor behavior | GATA3 recognized as a pioneer TF in breast cancer; ZnFn2 mutations were enriched in luminal B tumors (52%, 16/29 cases), and among high-GATA3 tumors were associated with worse 10-year survival than other GATA3 mutations; CRISPR modeling of R330fs showed redistribution of GATA3 occupancy at ~25% of genomic sites, with gain/loss of binding linked to EMT-related transcriptional changes (pqac-00000018, pqac-00000019) | Primary | Takaku et al., *Nature Communications*, 2018 (contextual mechanistic benchmark cited by 2024 work) | https://doi.org/10.1038/s41467-018-03478-4 | (pqac-00000018, pqac-00000019) |
| Breast cancer chromatin regulation | CHD4/NuRD restrains inappropriate GATA3 pioneer activity by nucleosome positioning over GATA3 motifs | In reprogramming experiments, CHD4 activity was necessary to prevent inappropriate chromatin opening by pioneer factor GATA3, supporting a proofreading role for chromatin remodeling in GATA3 site selection (pqac-00000020) | Primary | Saotome et al., *Nucleic Acids Research*, 2024 | https://doi.org/10.1093/nar/gkae025 | (pqac-00000020) |
| Urothelial carcinoma / diagnostic pathology | GATA3 IHC as luminal marker and subtype surrogate | In a 40-case cohort, a 20% positivity cutoff was used for subtype assignment; GATA3, CK20, and CK5/6 together stratified luminal vs basal tumors; basal subtype correlated with poorer prognostic parameters, while GATA3 alone showed no significant association with clinicopathologic parameters in this cohort (pqac-00000016) | Primary | Yassen et al., *Bulletin of the National Research Centre*, 2024 | https://doi.org/10.1186/s42269-024-01237-8 | (pqac-00000016) |
| Urothelial carcinoma / upper tract disease | IHC luminal-basal profiling with GATA3, CK5/6, CK20 | In UTUC, GATA3 was included in an IHC panel for luminal-basal stratification; UTUC with synchronous/metachronous bladder cancer had worse PFS (HR 3.570, 95% CI 1.508–8.453, p=0.004) but not OS (HR 1.279, 95% CI 0.513–3.190, p=0.597), showing real-world use of GATA3-containing subtype panels in prognostic modeling (pqac-00000017) | Primary | Meireles et al., *Biomedicines*, 2024 | https://doi.org/10.3390/biomedicines12092154 | (pqac-00000017) |
| Breast and urothelial carcinoma / cross-tumor diagnostic performance | Nuclear GATA3 IHC marker; cut-off choice affects sensitivity/specificity | In a 235-case cross-tumor series, GATA3 was expressed in **all primary** and **93% of metastatic** urinary carcinomas, and in **94% of primary** and **80% of metastatic** breast carcinomas; authors noted raising the positivity cut-off increased specificity but reduced sensitivity (pqac-00000009) | Primary | Bota et al., *Monaldi Archives for Chest Disease*, 2024 | https://doi.org/10.4081/monaldi.2023.2641 | (pqac-00000009) |


*Table: This table condenses 2023-2024 evidence on human GATA3 across immune, breast, and urothelial contexts. It highlights mechanisms, recent experimental findings, and quantitative results useful for functional annotation and translational interpretation.*